Showing results (1-10 of 77) with videos related to
Sort By:
Pageof 8
Muscle & Nerve|December 27, 2019
Improvements in health status and utility associated with ataluren for the treatment of nonsense mutation Duchenne muscular dystrophyErik Landfeldt, Christopher Lindberg, Thomas SejersenActa Paediatrica (Oslo, Norway : 1992)|September 7, 2018
A mini-review and implementation model for using ataluren to treat nonsense mutation Duchenne muscular dystrophyErik Landfeldt, Thomas Sejersen, Már TuliniusFrontiers in Bioscience (Scholar Edition)|January 2, 2013
Genetic spectrum of cardiomyopathies with neuromuscular phenotypeAnna Kostareva, Thomas Sejersen, Gunnar SjobergThe Journal of Pediatrics|June 1, 2016
Parents' Experiences and Wishes at End of Life in Children with Spinal Muscular Atrophy Types I and IIMalin Lövgren, Thomas Sejersen, Ulrika KreicbergsLakartidningen|April 20, 2005
[Hereditary cardiomyopathies: a review. Mutation of structural proteins a common cause of hereditary cardiomyopathy]Gunnar Sjöberg, Anna Kostareva, Thomas SejersenEuropean Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|September 8, 2016
Information and treatment decisions in severe spinal muscular atrophy: A parental follow-upMalin Lövgren, Thomas Sejersen, Ulrika KreicbergsJournal of Pediatric Rehabilitation Medicine|February 20, 2025
Experiences of families of children with spinal muscular atrophy and the healthcare professionals supporting them during the COVID-19 pandemic: A nationwide studyCamilla Udo, Malin Lövgren, Thomas Sejersen, et al.Drug Design, Development and Therapy|June 23, 2022
Disease Modifying Therapies for the Management of Children with Spinal Muscular Atrophy (5q SMA): An Update on the Emerging EvidenceHelgi Thor Hjartarson, Kristofer Nathorst-Böös, Thomas SejersenEuropean Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|August 16, 2022
Survival in patients diagnosed with SMA at less than 24 months of age in a population-based setting before, during and after introduction of nusinersen therapy. Experience from SwedenAnders Berglund, Sara Berkö, Erik Lampa, et al.Methods in Molecular Biology (Clifton, N.J.)|May 5, 2017
Assaying Mitochondrial Respiration as an Indicator of Cellular Metabolism and FitnessNatalia Smolina, Joseph Bruton, Anna Kostareva, et al.Pageof 8